课题基金 / 基金详情

Evaluating and Extending Our Hypothetical Model of Alzheimer's Biomarkers

Evaluating and Extending Our Hypothetical Model of Alzheimer's Biomarkers
评估和扩展我们的阿尔茨海默病生物标志物假设模型
批准号:
8580664
负责人:
CLIFFORD R. JACK
金额:
$55.97万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1993
资助国家:
美国
项目状态:
已结题
起止时间:
1993-06-01 至 2018-05-31

项目摘要

项目成果

CLIFFORD R. JACK的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): A central insight gained from the current cycle of AG011378 is that in someone destined to develop Alzheimer's disease (AD) dementia, different biomarkers become abnormal in a sequential manner. Based on results from the current grant cycle, we proposed a biomarker-based disease model which posits that amyloid biomarkers become abnormal first, perhaps 15 years before the onset of overt clinical symptoms. Neuronal injury biomarkers become abnormal next, followed later by incident mild cognitive impairment (MCI). While we believe the model is largely correct, some in the field dispute this and therefore empiric evaluation is needed. This renewal will evaluate and extend our hypothetical biomarker model by following a large, population- based cohort of cognitively normal (CN) subjects studied with biomarkers for up to 10 years, and thus address major gaps in understanding disease progression. The central objective of this renewal is to understand how imaging biomarkers of AD pathophysiology (AD-P) change in the preclinical and early MCI phases of AD in relation to each other, and then to identify practical implications of sequential biomarker change. A notable strength of this renewal is our large - perhaps the largest in the world - existing cohort of CN subjects from an epidemiologically defined sample who have already undergone all imaging studies at baseline. Subjects for this renewal (n~1500) will be participants in the Mayo Clinic Study of Aging, an epidemiological sample of non- demented subjects in Olmsted County, MN. As outlined in the Introduction, we have significantly revised this A1 application in response to the study section critique. Aim 1. Establish cut-points for amyloid PET, TF-fMRI, FDG-PET, sMRI, CSF A¿42 and tau demarcating normal from abnormal. A major question in the field at present is how to appropriately define AD biomarker cut-points that separate normal from abnormal. Aim 2. Model validation: test the hypothesis that AD imaging biomarkers become abnormal in a specific temporal order. Our initial model was consistent with the amyloid cascade hypothesis in that amyloid biomarkers become abnormal first followed by FDG-PET and MR. However, this has been challenged. We will formally test this hypothesis using three different approaches and will extend and refine our existing model of biomarker evolution based on these findings. These results could alter current notions of AD pathogenesis. Aim 3. To integrate AD-P biomarker evidence with other predictors to enhance risk prediction for incident MCI. This will provide practical guidance for using AD biomarkers for clinical counseling. Aim 4. To provide practical guidance for using AD biomarkers in secondary prevention clinical trials.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SCAN: Standardized Centralized Alzheimer's and Related Dementias Neuroimaging
  • 批准号:
    10400153
  • 项目类别:
  • 资助金额:
    $160.2万
  • 财政年份:
    2020
  • 负责人:
    CLIFFORD R. JACK
  • 依托单位:
SCAN: Standardized Centralized Alzheimer's and Related Dementias Neuroimaging
  • 批准号:
    9976317
  • 项目类别:
  • 资助金额:
    $165.72万
  • 财政年份:
    2020
  • 负责人:
    CLIFFORD R. JACK
  • 依托单位:
SCAN: Standardized Centralized Alzheimer's and Related Dementias Neuroimaging
  • 批准号:
    10335694
  • 项目类别:
  • 资助金额:
    $64.16万
  • 财政年份:
    2020
  • 负责人:
    CLIFFORD R. JACK
  • 依托单位:
SCAN: Standardized Centralized Alzheimer's and Related Dementias Neuroimaging
  • 批准号:
    10819797
  • 项目类别:
  • 资助金额:
    $58.26万
  • 财政年份:
    2020
  • 负责人:
    CLIFFORD R. JACK
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: